By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OncoGenex Pharmaceuticals Inc. 

1522 217th Place SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600


OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678


October 1991


Founders: Martin Gleave and Scott Daniel Cormack

CEO and Founder: Scott Cormack

CMO (Medical): Cindy Jacobs

CFO: John Bencich


Please click here for.


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: OncoGenex
Symbol: OGXI

Company News
OncoGenex (OGXI) Announces Results From the Phase III ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer 10/13/2016 6:53:03 AM
OncoGenex (OGXI) Hires Advisor, Seeks Strategic Alternatives After Cancer Drug Custirsen Study Fails 8/16/2016 6:29:22 AM
OncoGenex (OGXI) Reports Financial Results For Second Quarter 2016 8/5/2016 7:27:21 AM
OncoGenex (OGXI) To Report Second Quarter 2016 Financial Results On August 4, 2016 7/22/2016 6:21:59 AM
OncoGenex (OGXI) Reports Financial Results For First Quarter 2016 5/13/2016 6:27:57 AM
OncoGenex (OGXI) To Report First Quarter 2016 Financial Results On May 12, 2016 4/29/2016 6:31:59 AM
OncoGenex (OGXI) To Present At The 15th Annual Needham Healthcare Conference 4/6/2016 6:40:40 AM
OncoGenex (OGXI) Reports Financial Results for Year End 2015 3/10/2016 6:34:33 AM
OncoGenex (OGXI) To Report Fourth Quarter And Year End 2015 Financial Results On March 9, 2016 2/25/2016 9:28:24 AM
OncoGenex (OGXI) Pink-Slips 27% of Staff to Save Money for Ongoing Clinical Trials 2/4/2016 2:09:07 PM